Novartis revenue by segment 2025| ��ƽ��

Novartis AG's revenue from 2014 to 2025, by segment (in billion U.S. dollars)

Characteristic	Pharmaceuticals (Innovative Medicines)	Sandoz	Consumer Health*	Vaccines and Diagnostics**	Alcon***	Established brands
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-
-	-	-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Release date

February 2026

More information

Region

Worldwide

Survey time period

2014 to 2025

Supplementary notes

This statistic was assembled from several Novartis' annual reports. All figures are rounded.
* In 2015, a joint venture between Novartis OTC and GSK Consumer Healthcare was formed.
** In 2015, the vaccines business was sold to GSK.
*** During 2019, eye care division Alcon was spun off and became an own company. Thus, Alcon's revenues are not included from this year onwards.
**** The spin-off of Sandoz brought changes in the structure of segments: Innovative Medicines became "Promoted brands" and the rest "Established brands".

Citation formats

In 2025, Novartis AG made approximately ** billion U.S. dollars from its promoted brand pharmaceuticals business segment. In the year 2023, the Swiss company spun off its generic drug division Sandoz, leading to lower revenue figures compared to previous years.

Novartis’ revenue

Novartis AG, one of the largest pharmaceutical companies worldwide, generated total revenues of about ** billion U.S. dollars in 2025, which was an increase of around **** billion dollars compared to the year prior. The company, which is based in Switzerland, made the largest single share of its revenues in the United States (over ** billion U.S. dollars). Roughly ** billion U.S. dollars were generated in Europe.

Global net income rankings

Johnson & Johnson from the United States is also among the world's top biotech and pharmaceutical companies, based on net income, as of 2024. The company’s net income amounted to over ** billion U.S. dollars. Novartis stood in fifth place that year with a net income of about ** billion U.S. dollars.